Results 31 to 40 of about 1,042 (177)

Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions. [PDF]

Allergy
ABSTRACT Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. The clinical presentation of AD is heterogeneous and is characterized by a relapsing and remitting course. Most patients suffer from mild AD while approximately 5% to 20% experience severe disease activity, which often requires systemic treatment ...
de Bruin-Weller MS, Boesjes CM, Achten RA, Beck LA, Irvine AD, Vestergaard C, de Graaf M, van Wijk F, Bakker DS, Weidinger S.   +9 more
europepmc   +2 more sources

Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial

Dermatology and Therapy, 2023
Introduction Atopic dermatitis (AD), with its signs and symptoms of pruritus, dryness, and erythema, severely reduces the quality of life (QOL) of affected patients.
Kenji Kabashima, Takayo Matsumura, Hiroshi Komazaki, Makoto Kawashima, The Nemolizumab-JP01 Study Group   +4 more
doaj   +1 more source

[Translated article] Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis

Actas Dermo-Sifiliográficas, 2022
Interleukin 31 (IL-31) is a neurocytokine that stimulates sensory neurons involved in pruritus. It contributes to skin barrier inflammation, dysfunction, and remodeling.
E. Serra-Baldrich, L.F. Santamaria-Babí, J. Francisco Silvestre   +2 more
doaj   +1 more source

Nemolizumab: un innovador tratamiento biológico para el control de la interleuquina 31 (IL-31) clave en la dermatitis atópica y el prurigo nodular

Actas Dermo-Sifiliográficas, 2022
Resumen: La citoquina IL-31 es una neurocitoquina que estimula las neuronas sensoriales relacionadas con el picor, contribuye a la inflamación, la disfunción y remodelación de la barrera epidérmica. Al interrelacionar los sistemas inmunológico y nervioso
E. Serra-Baldrich, L.F. Santamaría-Babí, J. Francisco Silvestre   +2 more
doaj   +1 more source

Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis

Pharmaceutics, 2023
Atopic dermatitis (AD), a pruritic, inflammatory chronic disease with multifactorial pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not only the immunologic dysfunction and microbiome dysbiosis but also the recovery
Raquel Leao Orfali, Valeria Aoki
doaj   +1 more source

Safety and Efficacy of Nemolizumab for Patients with Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trial

Frontiers in Immunology, 2022
BackgroundNemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus.ObjectiveThis study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of ...
Junqin Liang, Fengxia Hu, Maoli Dan, Yingbing Sang, Kailibinuer Abulikemu, Qian Wang, Yongzhen Hong, Xiaojing Kang   +7 more
doaj   +1 more source

Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus [PDF]

, 2020
Background: Nemolizumab targets the IL-31 receptor a subunit involved in atopic dermatitis (AD) pathogenesis. Objective: We sought to evaluate a new dosing strategy of nemolizumab in patients with AD.
Ahmad, Faiz, Alexis, Andrew, Bouaziz, Jean-David, Clucas, Alan, Lindsey, Lisa, Murrell, Dedee F., Piketty, Christophe, Pinter, Andreas, Poulin, Yves, Pulka, Grażyna, Silverberg, Jonathan I., Wollenberg, Andreas   +11 more
core   +1 more source

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran, Meier, Katharina, Solimani, Farzan   +2 more
core   +1 more source

New Topical and Systemic Treatments for Atopic Dermatitis. [PDF]

Clin Exp Allergy
This review summarises new topical and systemic treatments for atopic dermatitis, their relative effectiveness, and important safety data. ABSTRACT Atopic dermatitis is an inflammatory skin condition characterised by pruritus and a chronic relapsing–remitting course.
Mirali S, Drucker AM.
europepmc   +2 more sources

Human and computational models of atopic dermatitis:A review and perspectives by an expert panel of the International Eczema Council [PDF]

, 2018
Atopic dermatitis (AD) is a prevalent disease worldwide and is associated with systemic comorbidities representing a significant burden on patients, their families, and society. Therapeutic options for AD remain limited, in part because of a lack of well-
Bieber, Thomas, Bissonette, Robert, Brown, Sara J., Dhar, Sandipan, Eyerich, Kilian, Guttman-Yassky, Emma, Hijnen, Dirk J., Irvine, Alan, Paller, Amy S., Perez White, Bethany E., Reynolds, Nick J., Tanaka, Reiko J., Thyssen, Jacob P., Vestergaard, Christian, Werfel, Thomas, Wollenberg, Andreas   +15 more
core   +5 more sources